Saxagliptin: a new option for the management of type 2 diabetes

Future Prescriber Pub Date : 2009-08-13 DOI:10.1002/fps.50
Marc Evans MRCP, MD
{"title":"Saxagliptin: a new option for the management of type 2 diabetes","authors":"Marc Evans MRCP, MD","doi":"10.1002/fps.50","DOIUrl":null,"url":null,"abstract":"<p>Incretin-based therapies for the treatment of diabetes mellitus (T2DM) present a new approach to disease management. Over recent years, several new drugs have entered the marketplace, and NICE have recently issued guidance on how best to incorporate these new drugs into treatment regimens. In this article, Marc Evans reviews saxagliptin, a dipeptidyl peptidase-IV (DPP-IV) inhibitor, and considers its potential clinical use. Copyright © 2009 John Wiley &amp; Sons, Ltd.</p>","PeriodicalId":100566,"journal":{"name":"Future Prescriber","volume":"10 3","pages":"13-17"},"PeriodicalIF":0.0000,"publicationDate":"2009-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/fps.50","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future Prescriber","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/fps.50","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Incretin-based therapies for the treatment of diabetes mellitus (T2DM) present a new approach to disease management. Over recent years, several new drugs have entered the marketplace, and NICE have recently issued guidance on how best to incorporate these new drugs into treatment regimens. In this article, Marc Evans reviews saxagliptin, a dipeptidyl peptidase-IV (DPP-IV) inhibitor, and considers its potential clinical use. Copyright © 2009 John Wiley & Sons, Ltd.

沙格列汀:治疗2型糖尿病的新选择
以肠促胰岛素为基础的治疗糖尿病(T2DM)提供了一种新的疾病管理方法。近年来,一些新药进入市场,NICE最近发布了关于如何最好地将这些新药纳入治疗方案的指南。在本文中,Marc Evans综述了沙格列汀,一种二肽基肽酶- iv (DPP-IV)抑制剂,并考虑了其潜在的临床应用。版权所有©2009 John Wiley &儿子,有限公司
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信